Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 2
2012 1
2013 4
2014 4
2015 2
2016 3
2017 2
2019 5
2020 6
2021 5
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma"
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Eligible patients were adults (18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) pe …
Eligible patients were adults (18 years) with previously untreated locally advanced or metastatic non-small-c …
Extending survival of stage IV non-small cell lung cancer.
Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. Carnio S, et al. Semin Oncol. 2014 Feb;41(1):69-92. doi: 10.1053/j.seminoncol.2013.12.013. Epub 2013 Dec 21. Semin Oncol. 2014. PMID: 24565582 Free article. Review.
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced or metastatic disease. ...Currently no agents are specifically approved for the treatment of squamous cell carcinoma of t …
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced …
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J, Yu X, Huang D, Ma Z, Gao B, Cui J, Chu Q, Zhou Q, Sun M, Day D, Wu J, Pan H, Wang L, Voskoboynik M, Wang Z, Liu Y, Li H, Zhang J, Peng Y, Wu YL. Zhao J, et al. J Immunother Cancer. 2023 Feb;11(2):e006055. doi: 10.1136/jitc-2022-006055. J Immunother Cancer. 2023. PMID: 36808075 Free PMC article. Clinical Trial.
BACKGROUND: Some patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) respond poorly to anti-programmed cell death protein 1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) treatments. ...Cohorts A and F inclu …
BACKGROUND: Some patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) resp …
Economic analyses of immune-checkpoint inhibitors to treat lung cancer.
Vergnenegre A, Chouaid C. Vergnenegre A, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):365-371. doi: 10.1080/14737167.2021.1863790. Epub 2020 Dec 24. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33306411 Review.
Introduction: Total lung-cancer-management costs are increasing dramatically. The widespread use of immune-checkpoint inhibitors (ICIs) explains this rise in large part and financially impacts healthcare systems. ...Cancers analyzed were non-squamous non …
Introduction: Total lung-cancer-management costs are increasing dramatically. The widespread use of immune-checkpoint inhibitors (ICI …
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Brown T, et al. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Health Technol Assess. 2013. PMID: 23886301 Free PMC article. Review.
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic non-small cell lung cancer ( …
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recomm …
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C. Griesinger F, et al. Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001. Epub 2022 Aug 6. Lung Cancer. 2022. PMID: 36007281 Free article.
OBJECTIVES: To describe the impact of immune checkpoint inhibitors (ICIs) on treatment patterns and survival outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) in France and Germany. MATERIALS AND …
OBJECTIVES: To describe the impact of immune checkpoint inhibitors (ICIs) on treatment patterns and survival outcomes in patients with lo …
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer.
Manzo A, Carillio G, Montanino A, Sforza V, Palumbo G, Esposito G, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Botti G, Totaro G, Muto P, Picone C, Normanno N, Morabito A. Manzo A, et al. Expert Opin Drug Saf. 2020 Jul;19(7):775-783. doi: 10.1080/14740338.2020.1767584. Epub 2020 May 26. Expert Opin Drug Saf. 2020. PMID: 32400223 Review.
INTRODUCTION: Atezolizumab is a humanized monoclonal antibody against PD-L1 capable of enhancing antitumor immune activity, with a demonstrated activity as single agent in patients with advanced non-small-cell lung cancer (NSCLC). AREAS COVERED: …
INTRODUCTION: Atezolizumab is a humanized monoclonal antibody against PD-L1 capable of enhancing antitumor immune activity, with a demonstra …
EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.
Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E. Helland Å, et al. Cancer Treat Res Commun. 2022;33:100636. doi: 10.1016/j.ctarc.2022.100636. Epub 2022 Sep 16. Cancer Treat Res Commun. 2022. PMID: 36155129 Free article.
BACKGROUND: Testing for epidermal growth factor receptor mutation (EGFRm) status is a prerequisite to identify eligible patients for tyrosine kinase inhibitors (TKI) treatment. However, EGFR testing of patients with non-small cell lung cancer (NSCLC) i …
BACKGROUND: Testing for epidermal growth factor receptor mutation (EGFRm) status is a prerequisite to identify eligible patients for tyrosin …
Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
Visser S, Hou J, Bezemer K, de Vogel LL, Hegmans JPJJ, Stricker BH, Philipsen S, Aerts JGJV. Visser S, et al. BMC Cancer. 2019 May 14;19(1):440. doi: 10.1186/s12885-019-5645-x. BMC Cancer. 2019. PMID: 31088547 Free PMC article.
BACKGROUND: Palliative pemetrexed-based chemotherapy remains a standard of care treatment for the majority of patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Currently, no predictive markers for pemet …
BACKGROUND: Palliative pemetrexed-based chemotherapy remains a standard of care treatment for the majority of patients with advanced …
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M. Baptiste Oudart J, et al. Lung Cancer. 2024 Apr;190:107508. doi: 10.1016/j.lungcan.2024.107508. Epub 2024 Feb 19. Lung Cancer. 2024. PMID: 38428265 Free article. Clinical Trial.
BACKGROUND: STK11/LKB1 mutations have been associated with primary resistance to PD-1 axis inhibitors and poor prognosis in advanced KRAS-mutant lung adenocarcinoma. This study aimed to assess the prognostic significance of STK11/LKB1 alterations in localized …
BACKGROUND: STK11/LKB1 mutations have been associated with primary resistance to PD-1 axis inhibitors and poor prognosis in advanced …
34 results